ANALYSIS OF ROLE OF MAGNESIUM SULPHATE IN ECLAMPSIA AND PRE-ECLAMPSIA

Introduction: Magnesium sulfate (MgSC4) is the agent most commonly used for treatment of eclampsia and prophylaxis of eclampsia in patients with severe pre-eclampsia. Aims and objectives: The basic aim of the study is to analyze the role of magnesium sulphate in eclampsia and pre-eclampsia women in Pakistan. Material and methods: This descriptive study was conducted in King Edward Medical University, Lahore during March 2018 to November 2018. This study was done with the permission of ethical committee of hospital. The data was collected from 100 female patients. Data was collected through a systematically designed questionnaire. The survey included facility characteristics, MgSO4 availability and potential barriers to its access, availability and distribution of clinical protocols for MgSO4 use, MgSO4 dosing regimens for the treatment of pre-eclampsia and eclampsia, institutional capacity to manage MgSO4 toxicity, and preferences for different options of simplified MgSO4 regimens. Results: The data were collected from 100 female patients. Respondents reported that 24.3% of all facilities used MgSO4 for treatment of mild pre-eclampsia (35.1% in Latin America, 22.7% in Asia and 18.6% in Africa). Over 90% of health facilities in all three regions used MgSO4 for treatment of severe pre-eclampsia and eclampsia. With respect to the diagnosis and management of MgSO4 toxicity, 27.8% of all facilities reported having the capacity to routinely measure serum magnesium concentration. Conclusion: It is concluded that here was no association between adverse outcomes and maternal serum magnesium concentrations and no maternal mortality occurred. Magnesium sulphate was effective in preventing recurrence of eclamptic fits and safe for both mother and fetus.